Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05778188
PHASE2

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia

Sponsor: ReAlta Life Sciences, Inc.

View on ClinicalTrials.gov

Summary

Hypoxic-ischemic encephalopathy (HIE) affects approximately 4,000 to 12,000 persons annually in the United States. Mortality from HIE has been reported up to 60%, with at least 25% of survivors left with significant neurocognitive disability. Despite this vital unmet medical need, no pharmacological adjunct or alternative therapy has proven beneficial in improving outcomes in neonatal HIE. RLS-0071 is a novel peptide being developed for the treatment of neonatal HIE. This study is designed to evaluate the safety and tolerability of RLS-0071 in the treatment of newborns with moderate or severe HIE.

Official title: A Phase 2, Two-Stage, Randomized, Double-Blind, Placebo-Controlled, Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia With Long-Term Follow-Up

Key Details

Gender

All

Age Range

Any - 10 Hours

Study Type

INTERVENTIONAL

Enrollment

42

Start Date

2023-07-27

Completion Date

2026-04

Last Updated

2025-10-24

Healthy Volunteers

No

Interventions

DRUG

RLS-0071

RLS-0071 (unit strength 10 mg/mL) will be administered by infusion for a dose level of 3 or 10 mg/kg. Planned infusion duration is 10 minutes for all dose levels.

DRUG

Placebo

Placebo control (commercial sterile saline) will be administered by infusion at a volume matched to RLS-0071 (3 or 10 mg/kg). Planned infusion duration is 10 minutes for all matched dose levels.

Locations (15)

Study Site 016

Little Rock, Arkansas, United States

Study Site 013

Orange, California, United States

Study Site 020

San Diego, California, United States

Study Site 019

San Diego, California, United States

Study Site 001

Gainesville, Florida, United States

Study Site 018

Miami, Florida, United States

Study Site 010

Orlando, Florida, United States

Study Site 014

Indianapolis, Indiana, United States

Study Site 012

Lexington, Kentucky, United States

Study Site 002

Boston, Massachusetts, United States

Study Site 006

St Louis, Missouri, United States

Study Site 003

Durham, North Carolina, United States

Study Site 021

Cleveland, Ohio, United States

Study Site 022

Fort Worth, Texas, United States

Study Site 005

Morgantown, West Virginia, United States